Advancements in the co-formulation of biologic therapeutics

Documentos científicos relacionados a la COVID-19

Advancements in the co-formulation of biologic therapeutics

Solo ficha. El repositorio marca este trabajo como «Acceso restringido»: el PDF no es público, así que aquí no hay texto para leer. Ver la ficha en el repositorio.

Resumen

Biologic therapeutics are the medicines of the future and are destined to transform the approaches by which the causes and symptoms of diseases are cured and alleviated. These approaches will be accelerated through the development of novel strategies that target multiple pharmacologically active sites using a combination of different biologics, or mixtures of biologics and small molecule therapeutics. However, for this potential to be realised, advancements in co-formulation strategies for biologic therapeutics must be established. This review describes the current and emerging developments within this field and highlights the challenges and potential solutions, that will pavethe-way towards their clinical translation.

Palabras clave

Active pharmaceutical ingredients Biologic Co-formulation Nucleic acids Proteins Targeted Vaccines

Tesauro de su biblioteca

Coronavirus COVID-19 SARS-CoV-2 Síndrome respiratorio agudo grave

Citar

APA 7

Universidad Jorge Tadeo Lozano. (s. f.). Advancements in the co-formulation of biologic therapeutics. https://hdl.handle.net/20.500.12010/12585

ICONTEC

Advancements in the co-formulation of biologic therapeutics. Bogotá: Universidad Jorge Tadeo Lozano. Disponible en: https://hdl.handle.net/20.500.12010/12585

BibTeX

@article{spora,
  title = {{Advancements in the co-formulation of biologic therapeutics}},
  publisher = {Universidad Jorge Tadeo Lozano},
  url = {https://hdl.handle.net/20.500.12010/12585}
}

Armada con los datos del repositorio: revísala antes de entregarla. Para citar una página, ábrela en el lector.